Skip to main content
Midas Edge

RHYTHM PHARMACEUTICALS INC

For the period ended Dec 31, 2024. Filed Feb 28, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 28, 2025

RYTM$113.95+0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Convertible Preferred Stock & Stockholders’ Equity

(in thousands, except share data)

​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​
​ · ​ · Series A Convertible · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Preferred Stock · ​ · Common Stock · ​ · Paid-In · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders’
​ · Shares · Amount · Shares · Amount · Capital · Income (Loss) · ​ · Deficit · Equity
Balance at December 31, 2021​—​​—​50,283,574​​50​​813,041​​(1)​​(528,939)​​284,151
Stock compensation expense​———​—​19,831​—​​—​19,831
Issuance of common stock in connection with ESPP​——92,932​​—​626​—​​—​626
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units​——855,923​1​9,751​—​​—​9,752
Issuance of common stock upon completion of public offering, net of offering costs​——5,380,000​​5​131,107​—​​—​131,112
Net unrealized loss on marketable securities​———​—​—​(91)​​—​(91)
Net loss​—​​—​—​​—​​—​​—​​(181,119)​​(181,119)
Balance at December 31, 2022​—$—56,612,429​$56$974,356$(92)​$(710,058)$264,262
Stock compensation expense​———​—​32,553​—​​—​32,553
Issuance of common stock in connection with ESPP​——49,819​​​​1,053​—​​—​1,053
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units​——745,066​1​7,467​—​​—​7,468
Issuance of common stock upon completion of ATM equity offering, net of offering costs​—​​—​2,019,245​​2​​48,873​​—​​—​​48,875
Foreign currency translation adjustment​—​​—​—​​—​​—​​(140)​​—​​(140)
Net unrealized gain on marketable securities​———​—​—​366​​—​366
Net loss​—​​—​—​​—​​—​​—​​(184,678)​​(184,678)
Balance at December 31, 2023​—$—59,426,559​$59$1,064,302$134​$(894,736)$169,759
Issuance of Series A Preferred Stock, net of $2,250 of issuance costs​150,000​​138,850​—​​—​​—​​—​​—​​—
Stock compensation expense​—​​—​—​—​39,682​—​​—​39,682
Issuance of common stock in connection with ESPP​—​​—​44,554​​—​​1,270​​—​​—​​1,270
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units​—​​—​1,742,803​​2​​15,972​​—​​—​​15,974
Issuance of common stock as consideration for LGC license​—​​—​432,143​​—​​18,716​​—​​—​​18,716
Issuance of common stock upon completion of ATM equity offering, net of $1,125 offering costs​—​​—​744,595​​—​​41,073​​—​​—​​41,073
Accretion of preferred stock dividends​—​​3,970​—​​—​​(3,970)​​—​​—​​(3,970)
Foreign currency translation adjustment​—​​—​—​​—​​—​​2​​—​​2
Net unrealized loss on marketable securities​—​​—​—​—​—​(175)​​—​(175)
Net loss​—​​—​—​—​—​—​​(260,602)​(260,602)
Balance at December 31, 2024​150,000​$142,820​62,390,654​$61​$1,177,045​$(39)​$(1,155,338)​$21,729
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.